Revive Therapeutics’ (TSXV:RVV,OTCQB:RVVTF) stocks jumped by 43 percent on Thursday after the company announced that it is expanding its product pipeline by developing cannabinoid-based therapeutics specifically for liver diseases. Over the last five trading days, the stock is up by 60 percent.

Novel therapies for serious and unmet needs

Revive’s core business is on the research and development of treatments for medical needs that are “serious and unmet.” Included in its current clinical pipeline are therapies for kidney stones and gout.
A research note by BioNap stated that Revive’s entry into cannabinoid research, “is not a big stretch for Revive.” In fact, the company recently announced the initiation of Phase 2 of its clinical study for REV-004 or Bucillamine, for the treatment of cystinuria, a rare genetic disorder resulting in kidney stone formation.
Revive prides itself in its “bioinformatics platform” that was designed, “to identify repurposed and innovative drug treatments.” A number of repurposed drug and plant-derived candidates have already been identified using this platform, including cannabinoids. The company’s focus is now on cannabis-derived or cannabis-related drug candidates, stating that “[W]e believe this strategy offers the potential for development of highly differentiated drug candidates that are superior to current standards of care, as well as new intellectual property through the combination of repurposed drug candidates and cannabis-related drug candidates.” Revive also stated in their presentation that the company has identified diseases that may benefit from cannabinoid-based therapeutics.

Cannabis therapy for liver diseases

No details have been given on what specific liver disease the company is targeting, although Craig Leon, CEO of Revive said that the company has identified “potential cannabinoid-based lead opportunities in a number of liver diseases.”
Dr. Pritesh Kumar, Scientific Advisor for the Company, offered little detail as well but did state that, “we will be investigating in several pre-clinical research models.”

Liver disease market and cannabinoid opportunities

This is not the first time a biotech or pharmaceutical company has expanded into the cannabis space. Currently, there are three cannabinoid products approved in the US or Europe: Sativex by GW Pharmaceuticals (NASDAQ:GWPH), Marinol by AbbVie (NYSE:ABBV), and Cesamet by Meda Pharmaceuticals.
The global liver disease treatment market was valued at US $7,498 million in 2014, with an estimated growth over US $1,2095.0 million by 2022 due to a growing geriatric population, as well as rising liver ailments.
On the other hand, the cannabis industry has only begun its rise to an estimated $21.8 billion by 2020. 2016 saw huge strides as legalization both in Canada and the US made headlines. More importantly, the cannabis business will only grow even further in the coming year alone.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less